Financial Analysis: Cellectis (CLLS) vs. Zynerba Pharmaceuticals (ZYNE)

Cellectis (NASDAQ: CLLS) and Zynerba Pharmaceuticals (NASDAQ:ZYNE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, profitability, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Cellectis and Zynerba Pharmaceuticals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectis 0 1 5 0 2.83
Zynerba Pharmaceuticals 0 4 7 0 2.64

Cellectis currently has a consensus target price of $39.83, indicating a potential upside of 29.41%. Zynerba Pharmaceuticals has a consensus target price of $18.15, indicating a potential upside of 58.79%. Given Zynerba Pharmaceuticals’ higher possible upside, analysts clearly believe Zynerba Pharmaceuticals is more favorable than Cellectis.

Earnings and Valuation

This table compares Cellectis and Zynerba Pharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cellectis $56.46 million 19.59 -$67.25 million ($2.79) -11.03
Zynerba Pharmaceuticals $10,000.00 15,487.65 -$23.38 million ($2.59) -4.41

Zynerba Pharmaceuticals has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Zynerba Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.


This table compares Cellectis and Zynerba Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cellectis -217.25% -30.66% -25.66%
Zynerba Pharmaceuticals N/A -50.64% -45.05%

Insider and Institutional Ownership

16.4% of Cellectis shares are owned by institutional investors. Comparatively, 26.2% of Zynerba Pharmaceuticals shares are owned by institutional investors. 9.9% of Zynerba Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.


Zynerba Pharmaceuticals beats Cellectis on 9 of the 13 factors compared between the two stocks.

About Cellectis

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with's FREE daily email newsletter.

Leave a Reply